Kardiovaskuläre Morbidität und Mortalität bei Nierenerkrankungen

Schlüsselwörter

Albuminurie - chronische Niereninsuffizienz - orale Antikoagulation - Kalzimimetika

Keywords

albuminuria - renal insufficiency - oral anticoagulation - calcimimetics

• Literatur

• 1 Alonso A, Lopez FL, Matsushita K et al. Chronic kidney disease is associated with the incidence of atrial fibrillation. Circulation 2011; 123: 2946-2953
• 2 Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvasta­tin plus ezetimibe in patients with chronic kidney disease. Lancet 2011; 377: 2181-2192
• 3 Chang TI, Shilane D, Kazi DS et al. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol 2012; 23: 2042-2049
• 4 Chartsrisak K, Vipattawat K, Assanatham M et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol 2013; 14: 14
• 5 Charytan DM, Li S, Liu J et al. Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease. Circulation 2012; 126 Suppl. (Suppl. 01) 164-169
• 6 Chertow GM, Block GA, Correa-Rotter R et al. EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
• 7 Farkouh ME, Domanski M, Sleeper LA et al. FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-2384
• 8 Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
• 9 Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphorus and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
• 10 Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
• 11 Kendrick J, Cheung AK, Kaufman JS et al. HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922
• 12 Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease. Kidney Int 2011; 80: 17-28
• 13 O’Dell KM, Igawa D, Hsin J. New oral anti­coagulants for atrial fibrillation: a review of clinical trials. Clin Ther 2012; 34: 894-901
• 14 Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
• 15 Schmidt M, Daccarett M, Rittger H et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J CardiovascElectrophysiol 2011; 22: 1092-1098
• 16 Takahashi Y, Takahashi A, Kuwahara T et al. Renal function after catheter ablation of atrial fibrillation. Circulation 2011; 24: 2380-2387
• 17 Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease. JAMA 2012; 307: 674-684
• 18 Tobe SW, Clase CM, Gao P. on behalf of the ONTARGET and TRANSCEND Investigators et al. Cardiovascular and renal outcomes with telmisar- tan, ramipril, or both in people at high renal risk. Circulation 2011; 123: 1098-1107
• 19 Weng S, Sprague JE, Oh J et al. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS One 2013; 8: e54625
• 20 Yang F, Chou D, Schweitzer P et al. Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace 2010; 12: 1666-1672